Oragenics (OGEN) vs Sunshine Biopharma (SBFM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oragenics is the larger company by market cap ($2.1 million vs $1.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGEN | SBFM |
|---|---|---|
| Share price | $0.463 | $0.43 |
| Market cap | $2.09M | $1.85M |
| 1-day change | -7.38% | -38.57% |
| Forward P/E | — | 0.00 |
| EPS (TTM) | $-2.44 | $-9.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $24.30 |
| 52-week low | $0.46 | $0.356 |
| Distance from 52-week high | -68.07% | -98.23% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +12923.26% |
| Average volume | 29.43K | 5.25M |
| Shares outstanding | 4.51M | 4.31M |
| Employees | 3 | 50 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Sunshine Biopharma
SBFM stock →Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees
OGEN vs SBFM FAQ
Which is bigger, Oragenics or Sunshine Biopharma?
Oragenics (OGEN) is larger, with a market capitalization of $2.09M compared with $1.85M for Sunshine Biopharma (SBFM).
Are Oragenics and Sunshine Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.